MRI dye may shield cancer patients from nerve pain
NCT ID NCT00727922
First seen Nov 20, 2025 · Last updated May 16, 2026 · Updated 17 times
Summary
This study tested whether mangafodipir, an MRI contrast dye with antioxidant properties, could reduce nerve damage caused by the chemotherapy drug oxaliplatin. 23 cancer patients who already had moderate nerve problems from oxaliplatin received mangafodipir to see if it would allow them to continue their cancer treatment safely. The goal was to ease symptoms and improve quality of life without curing the underlying cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cochin
Paris, 75014, France
Conditions
Explore the condition pages connected to this study.